Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec in Anaplastic Thyroid Cancer
NCT00115739Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Feb 2004
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in anaplastic thyroid cancer (ATC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Overall Response Rate at 8 weeks. Started Feb 2004; status: terminated.
02
Drugs
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT00115739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115739.